Search

Your search keyword '"Nadeau, C."' showing total 307 results
Start Over Author "Nadeau, C."
307 results on '"Nadeau, C."'

1. Volatile Organic Compounds and the Relevance of Correcting for Background Signals in the Early Prediction of Bronchopulmonary Dysplasia in Preterm Infants

Author

Ghys, I., primary, Vanhaverbeke, K., additional, Elsedawi, B.F., additional, Vandermeersch, L., additional, Claessens, L., additional, Leys, A.-M., additional, Verhoustraeten, L., additional, Samson, N., additional, Nadeau, C., additional, Durand, M., additional, Petrof, B.J., additional, Van Overmeiren, P., additional, De Wispelaere, P., additional, Demeestere, K., additional, Van Langenhove, H., additional, Van Eyck, A., additional, Van Hoorenbeeck, K., additional, De Winter, B., additional, Verhulst, S.L., additional, Mulder, A., additional, Praud, J.-P., additional, Walgraeve, C., additional, and Lamote, K., additional

Published
2024
Full Text
View/download PDF

2. Exhaled Breath Volatile Organic Compounds: Window into Preterm Lung Disease? Proof-of-Concept Studies in Preterm Infants and Preterm Lambs

Author

Vanhaverbeke, K., primary, Fathi Elsedawi, B., additional, Vandermeersch, L., additional, Claessens, L., additional, Leys, A.-M., additional, Verhoustraeten, L., additional, Samson, N., additional, Nadeau, C., additional, Durand, M., additional, Petrof, B.J., additional, Van Overmeiren, P., additional, De Wispelaere, P., additional, Demeestere, K., additional, Van Langenhove, H., additional, Van Eyck, A., additional, Van Hoorenbeeck, K., additional, De Winter, B., additional, Verhulst, S.L., additional, Mulder, A., additional, Praud, J.-P., additional, Walgraeve, C., additional, and Lamote, K., additional

Published
2024
Full Text
View/download PDF

4. Need for risk-adapted therapy for malignant ovarian germ cell tumors: A large multicenter analysis of germ cell tumors' patients from French TMRG network

Author

Derquin, F., Floquet, A., Hardy-Bessard, A.C., Edeline, J., Lotz, J.P., Alexandre, J., Pautier, P., Angeles, M.A., Delanoy, N., Lefeuvre-Plesse, C., Cancel, M., Treilleux, I., Augereau, P., Lavoue, V., Kalbacher, E., Berton Rigaud, D., Selle, F., Nadeau, C., Gantzer, J., Joly, F., Guillemet, C., Pomel, C., Favier, L., Abdeddaim, C., Venat-Bouvet, L., Provansal, M., Fabbro, M., Kaminsky, M.C., Lortholary, A., Lecuru, F., Coquard, I. Ray, and de La Motte Rouge, T.

Published
2020
Full Text
View/download PDF

5. Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups

Author

Abba, J., Abboud, K., Arvieux, C., Bakrin, N., Delhorme, J.-B., Dartigues, P., Durand-Fontanier, S., Eveno, C., Fontaine, J., Gelli, M., Goere, D., Guyon, F., Lefevre, J., Lo Dico, R., Marchal, F., Nadeau, C., Paquette, B., Pezet, D., Pocard, M., Rousset, P., Sgarbura, O., Taibi, A., Tuech, J.-J., You, B., Villeneuve, L., Glehen, O., Kepenekian, V., Bouché, O., Gladieff, L., and Honore, C.

Published
2020
Full Text
View/download PDF

6. Prise en charge des tumeurs primitives et métastatiques du péritoine en période de pandémie CoViD-19. Pistes de réflexion et de priorisation du groupe RENAPE et BIG-RENAPE

Author

Abba, J., Abboud, K., Arvieux, C., Bakrin, N., Delhorme, J.-B., Dartigues, P., Durand-Fontanier, S., Eveno, C., Fontaine, J., Gelli, M., Goere, D., Guyon, F., Lefevre, J., Lo Dico, R., Marchal, F., Nadeau, C., Paquette, B., Pezet, D., Pocard, M., Rousset, P., Sgarbura, O., Taibi, A., Tuech, J.-J., You, B., Villeneuve, L., Glehen, O., Kepenekian, V., Bouché, O., Gladieff, L., and Honore, C.

Published
2020
Full Text
View/download PDF

10. 19P Long term sexual disorders among rare ovarian cancer survivors: The national GINECO case-control Vivrovaire Rare Tumors study

Author

Dubot, C., primary, Joly Lobbedez, F., additional, Ray Coquard, I.L., additional, Floquet, A., additional, Lefevre Arbogast, S., additional, Selle, F., additional, Berton-Rigaud, D., additional, Frank, S., additional, De La Motte Rouge, T., additional, Kalbacher, E., additional, Provansal Gross, M., additional, Lortholary, A., additional, Orfeuvre, H., additional, Alexandre, J., additional, Augereau, P., additional, Nadeau, C., additional, Kurtz, J.E., additional, Grellard, J-M., additional, Pautier, P., additional, and Gernier, F., additional

Published
2023
Full Text
View/download PDF

12. Prioritisation of colonoscopy services in colorectal cancer screening programmes to minimise impact of COVID-19 pandemic on predicted cancer burden: A comparative modelling study.

Author

van Wifferen, F, de Jonge, L, Worthington, J, Greuter, MJE, Lew, J-B, Nadeau, C, van den Puttelaar, R, Feletto, E, Yong, JHE, Lansdorp-Vogelaar, I, Canfell, K, Coupé, VMH, COVID-19 and Cancer Global Modelling Consortium (CCGMC) working group 2, van Wifferen, F, de Jonge, L, Worthington, J, Greuter, MJE, Lew, J-B, Nadeau, C, van den Puttelaar, R, Feletto, E, Yong, JHE, Lansdorp-Vogelaar, I, Canfell, K, Coupé, VMH, and COVID-19 and Cancer Global Modelling Consortium (CCGMC) working group 2

Abstract

OBJECTIVES: Colorectal cancer (CRC) screening with a faecal immunochemical test (FIT) has been disrupted in many countries during the COVID-19 pandemic. Performing catch-up of missed screens while maintaining regular screening services requires additional colonoscopy capacity that may not be available. This study aimed to compare strategies that clear the screening backlog using limited colonoscopy resources. METHODS: A range of strategies were simulated using four country-specific CRC natural-history models: Adenoma and Serrated pathway to Colorectal CAncer (ASCCA) and MIcrosimulation SCreening ANalysis for CRC (MISCAN-Colon) (both in the Netherlands), Policy1-Bowel (Australia) and OncoSim (Canada). Strategies assumed a 3-month screening disruption with varying recovery period lengths (6, 12, and 24 months) and varying FIT thresholds for diagnostic colonoscopy. Increasing the FIT threshold reduces the number of referrals to diagnostic colonoscopy. Outcomes for each strategy were colonoscopy demand and excess CRC-related deaths due to the disruption. RESULTS: Performing catch-up using the regular FIT threshold in 6, 12 and 24 months could prevent most excess CRC-related deaths, but required 50%, 25% and 12.5% additional colonoscopy demand, respectively. Without exceeding usual colonoscopy demand, up to 60% of excess CRC-related deaths can be prevented by increasing the FIT threshold for 12 or 24 months. Large increases in FIT threshold could lead to additional deaths rather than preventing them. CONCLUSIONS: Clearing the screening backlog in 24 months could avert most excess CRC-related deaths due to a 3-month disruption but would require a small increase in colonoscopy demand. Increasing the FIT threshold slightly over 24 months could ease the pressure on colonoscopy resources.

Published
2022

15. Diagnostic et prise en charge de l’incontinence urinaire d’effort de la femme adulte. Recommandations pour la pratique clinique du Collège national des gynécologues et obstétriciens français (CNGOF)

Author

Fritel, X., Fauconnier, A., Bader, G., Cosson, M., Debodinance, P., Deffieux, X., Denys, P., Dompeyre, P., Faltin, D., Fatton, B., Haab, F., Hermieux, J.-F., Kerdraon, J., Mares, P., Mellier, G., Michel-Laaengh, N., Nadeau, C., Robain, G., de Tayrac, R., and Jacquetin, B.

Published
2010
Full Text
View/download PDF

17. Prise en charge des tumeurs primitives et métastatiques du péritoine en période de pandémie CoViD-19. Pistes de réflexion et de priorisation du groupe RENAPE et BIG-RENAPE

Author

Glehen, O., primary, Kepenekian, V., additional, Bouché, O., additional, Gladieff, L., additional, Honore, C., additional, Abba, J., additional, Abboud, K., additional, Arvieux, C., additional, Bakrin, N., additional, Delhorme, J.-B., additional, Dartigues, P., additional, Durand-Fontanier, S., additional, Eveno, C., additional, Fontaine, J., additional, Gelli, M., additional, Goere, D., additional, Guyon, F., additional, Lefevre, J., additional, Lo Dico, R., additional, Marchal, F., additional, Nadeau, C., additional, Paquette, B., additional, Pezet, D., additional, Pocard, M., additional, Rousset, P., additional, Sgarbura, O., additional, Taibi, A., additional, Tuech, J.-J., additional, You, B., additional, and Villeneuve, L., additional

Published
2020
Full Text
View/download PDF

18. Treatment of primary and metastatic peritoneal tumors in the Covid-19 pandemic. Proposals for prioritization from the RENAPE and BIG-RENAPE groups

Author

Glehen, O., primary, Kepenekian, V., additional, Bouché, O., additional, Gladieff, L., additional, Honore, C., additional, Abba, J., additional, Abboud, K., additional, Arvieux, C., additional, Bakrin, N., additional, Delhorme, J.-B., additional, Dartigues, P., additional, Durand-Fontanier, S., additional, Eveno, C., additional, Fontaine, J., additional, Gelli, M., additional, Goere, D., additional, Guyon, F., additional, Lefevre, J., additional, Lo Dico, R., additional, Marchal, F., additional, Nadeau, C., additional, Paquette, B., additional, Pezet, D., additional, Pocard, M., additional, Rousset, P., additional, Sgarbura, O., additional, Taibi, A., additional, Tuech, J.-J., additional, You, B., additional, and Villeneuve, L., additional

Published
2020
Full Text
View/download PDF

19. The OncoSim-Breast cancer microsimulation model

Author

Yong, J.H.E., primary, Nadeau, C., additional, Flanagan, W., additional, Coldman, A., additional, Asakawa, K., additional, Garner, R., additional, Fitzgerald, N., additional, Yaffe, M., additional, and Miller, A.B., additional

Published
2020
Full Text
View/download PDF

23. 535P Long term quality of life after chemotherapy among nonepithelial ovarian cancer survivors: The case-control vivrovaire rare tumours study

Author

Joly Lobbedez, F., Ray-Coquard, I.L., Lefevre Arbogast, S., Grellard, J-M., Clarisse, B., Floquet, A., Selle, F., Berton-Rigaud, D., Frank, S., De La Motte Rouge, T., Kalbacher, E., Provansal Gross, M., A. lortholary, Orfeuvre, H., Alexandre, J., Augereau, P., Kurtz, J.E., Nadeau, C., Pautier, P., and Gernier, F.

Published
2022
Full Text
View/download PDF

25. The OncoSim Cancer Simulation Platform: A Tool to Project the Population Effects of Cancer Control Interventions in Canada

Author

Fitzgerald, N., primary, Gauvreau, C., additional, Memon, S., additional, Hussain, S., additional, Coldman, A., additional, Popadiuk, C., additional, Evans, W., additional, Wolfson, M., additional, Flanagan, W., additional, Nadeau, C., additional, Asakawa, K., additional, Garner, R., additional, and Miller, A., additional

Published
2018
Full Text
View/download PDF

27. Eotaxin and FGF enhance signaling through an Extracellular signal-related kinase (ERK)-dependent pathway in the pathogenesis of Eosinophilic Esophagitis

Author

Huang Jennifer J, Joh Jae, Fuentebella Judy, Patel Anup, Nguyen Tammie, Seki Scott, Hoyte Lisa, Reshamwala Neha, Nguyen Christine, Quiros Anthony, Bass Dorsey, Sibley Eric, Berquist William, Cox Kenneth, Kerner John, and Kari Nadeau C

Subjects
Immunologic diseases. Allergy, RC581-607
Abstract

Abstract Background Eosinophilic esophagitis (EoE) is characterized by the inflammation of the esophagus and the infiltration of eosinophils into the esophagus, leading to symptoms such as dysphagia and stricture formation. Systemic immune indicators like eotaxin and fibroblast growth factor were evaluated for possible synergistic pathological effects. Moreover, blood cells, local tissue, and plasma from EoE and control subjects were studied to determine if the localized disease was associated with a systemic effect that correlated with presence of EoE disease. Method Real-time polymerase chain reaction from peripheral blood mononuclear cells (PBMC), immunohistochemistry from local esophageal biopsies, fluid assays on plasma, and fluorescence-activated cell sorting on peripheral blood cells from subjects were used to study the systemic immune indicators in newly diagnosed EoE (n = 35), treated EoE (n = 9), Gastroesophageal reflux disease (GERD) (n = 8), ulcerative colitis (n = 5), Crohn's disease (n = 5), and healthy controls (n = 8). Result Of the transcripts tested for possible immune indicators, we found extracellular signal-regulated kinase (ERK), Bcl-2, bFGF (basic fibroblast growth factor), and eotaxin levels were highly upregulated in PBMC and associated with disease presence of EoE. Increased FGF detected by immunohistochemistry in esophageal tissues and in PBMC was correlated with low levels of pro-apoptotic factors (Fas, Caspase 8) in PBMC from EoE subjects. Plasma-derived bFGF was shown to be the most elevated and most specific in EoE subjects in comparison to healthy controls and disease control subjects. Conclusion We describe for the first time a possible mechanism by which increased FGF is associated with inhibiting apoptosis in local esophageal tissues of EoE subjects as compared to controls. Eotaxin and FGF signaling pathways share activation through the ERK pathway; together, they could act to increase eosinophil activation and prolong the half-life of eosinophils in local tissues of the esophagus in EoE subjects.

Published
2010
Full Text
View/download PDF

30. Cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for pseudomyxoma peritonei of appendicular and extra-appendicular origin

Author

Delhorme, J-B, primary, Severac, F, additional, Averous, G, additional, Glehen, O, additional, Passot, G, additional, Bakrin, N, additional, Marchal, F, additional, Pocard, M, additional, Lo Dico, R, additional, Eveno, C, additional, Carrere, S, additional, Sgarbura, O, additional, Quenet, F, additional, Ferron, G, additional, Goéré, D, additional, Brigand, C, additional, Abba, J, additional, Abboud, K, additional, Alyami, M, additional, Arvieux, C, additional, Balagué, G, additional, Barrau, V, additional, Ben Rejeb, H, additional, Bereder, J-M, additional, Berton-Rigaud, I, additional, Bibeau, F, additional, Bonnefoy, I, additional, Bouzard, D, additional, Bricault, I, additional, Carrère, S, additional, de Chaisemartin, C, additional, Chassang, M, additional, Chevallier, A, additional, Courvoisier, T, additional, Dartigues, P, additional, Dohan, A, additional, Dubreuil, J, additional, Dumont, F, additional, Faruch-Bilfeld, M, additional, Fontaine, J, additional, Fournier, L, additional, Gagniere, J, additional, Geffroy, D, additional, Ghouti, L, additional, Gilly, F-N, additional, Gladieff, L, additional, Guibal, A, additional, Guilloit, J-M, additional, Guyon, F, additional, Heyd, B, additional, Hoeffel, C, additional, Hordonneau, C, additional, Isaac, S, additional, Jourdan-Enfer, P, additional, Kaci, R, additional, Kianmanesh, R, additional, Labbé-Devilliers, C, additional, Lacroix, J, additional, Lelong, B, additional, Leroux-Broussier, A, additional, Lherm, Y, additional, Lorimier, G, additional, Malhaire, C, additional, Mariani, P, additional, Mathiotte, E, additional, Meeus, P, additional, Mery, E, additional, Msika, S, additional, Nadeau, C, additional, Ortega-Deballon, P, additional, Pellet, O, additional, Peyrat, P, additional, Pezet, D, additional, Pirro, N, additional, Poizat, F, additional, Porcheron, J, additional, Poulet, A, additional, Rat, P, additional, Rousselot, P, additional, Rousset, P, additional, Senellart, H, additional, Serrano, M, additional, Servois, V, additional, Sgabura, O, additional, Skanjeti, A, additional, Svrcek, M, additional, Tetreau, R, additional, Thibaudeau, E, additional, Touchefeu, Y, additional, Tuech, J-J, additional, Valmary-Degano, S, additional, Vaudoyer, D, additional, Velasco, S, additional, Verriele-Beurrier, V, additional, Villeneuve, L, additional, Wernert, R, additional, and Zinzindohoue, F, additional

Published
2018
Full Text
View/download PDF

34. Immunohistochemical evaluation of two antibodies against PD-L1 and prognostic significance of PD-L1 expression in epithelioid peritoneal malignant mesothelioma: A RENAPE study

Author

Valmary-Degano, S., primary, Colpart, P., additional, Villeneuve, L., additional, Monnien, F., additional, M'Hamdi, L., additional, Lang Averous, G., additional, Capovilla, M., additional, Bibeau, F., additional, Laverriere, M.-H., additional, Verriele-Beurrier, V., additional, Ben Rejeb, H., additional, Dartigues, P., additional, Hommell-Fontaine, J., additional, Gilly, F.-N., additional, Isaac, S., additional, Mery, E., additional, Abba, J., additional, Abboud, K., additional, Alyami, M., additional, Arvieux, C., additional, Bakrin, N., additional, Balagué, G., additional, Barrau, V., additional, Bereder, J.-M., additional, Berton-Rigaud, I., additional, Bonnefoy, I., additional, Bouzard, D., additional, Bricault, I., additional, Brigand, C., additional, Carrère, S., additional, de Chaisemartin, C., additional, Chassang, M., additional, Chevallier, A., additional, Courvoisier, T., additional, Dohan, A., additional, Dromain, C., additional, Dubreuil, J., additional, Dumont, F., additional, Eveno, C., additional, Faruch-Bilfeld, M., additional, Ferron, G., additional, Fournier, L., additional, Gagniere, J., additional, Geffroy, D., additional, Ghouti, L., additional, Gladieff, L., additional, Glehen, O., additional, Goéré, D., additional, Guibal, A., additional, Guilloit, J.-M., additional, Guyon, F., additional, Heyd, B., additional, Hoeffel, C., additional, Hordonneau, C., additional, Jourdan-Enfer, P., additional, Kaci, R., additional, Kianmanesh, R., additional, Labbé-Devilliers, C., additional, Lacroix, J., additional, Lelong, B., additional, Leroux-Broussier, A., additional, Lherm, Y., additional, Lo Dico, R., additional, Lorimier, G., additional, Malhaire, C., additional, Marchal, F., additional, Mariani, P., additional, Mathiotte, E., additional, Meeus, P., additional, Msika, S., additional, Nadeau, C., additional, Ortega-Deballon, P., additional, Passot, G., additional, Pellet, O., additional, Peyrat, P., additional, Pezet, D., additional, Pirro, N., additional, Pocard, M., additional, Poizat, F., additional, Porcheron, J., additional, Poulet, A., additional, Quenet, F., additional, Rat, P., additional, Rousselot, P., additional, Senellart, H., additional, Serrano, M., additional, Servois, V., additional, Sgabura, O., additional, Skanjeti, A., additional, Svrcek, M., additional, Tetreau, R., additional, Thibaudeau, E., additional, Touchefeu, Y., additional, Tuech, J.-J., additional, Vaudoyer, D., additional, Velasco, S., additional, Wernert, R., additional, and Zinzindohoue, F., additional

Published
2017
Full Text
View/download PDF

35. Rehabilitation augments hematoma clearance and attenuates oxidative injury and ion dyshomeostasis after brain hemorrhage

Author

Williamson, M., Dietrich, K., Hackett, Mark, Caine, S., Nadeau, C., Aziz, J., Nichol, H., Paterson, P., Colbourne, F., Williamson, M., Dietrich, K., Hackett, Mark, Caine, S., Nadeau, C., Aziz, J., Nichol, H., Paterson, P., and Colbourne, F.

Abstract

© 2016 American Heart Association, Inc.Background and Purpose - We assessed the elemental and biochemical effects of rehabilitation after intracerebral hemorrhage, with emphasis on iron-mediated oxidative stress, using a novel multimodal biospectroscopic imaging approach. Methods - Collagenase-induced striatal hemorrhage was produced in rats that were randomized to enriched rehabilitation or control intervention starting on day 7. Animals were euthanized on day 14 or 21, a period of ongoing cell death. We used biospectroscopic imaging techniques to precisely determine elemental and molecular changes on day 14. Hemoglobin content was assessed with resonance Raman spectroscopy. X-ray fluorescence imaging mapped iron, chlorine, potassium, calcium, and zinc. Protein aggregation, a marker of oxidative stress, and the distribution of other macromolecules were assessed with Fourier transform infrared imaging. A second study estimated hematoma volume with a spectrophotometric assay at 21 days. Results - In the first experiment, rehabilitation reduced hematoma hemoglobin content (P=0.004) and the amount of peri-hematoma iron (P<0.001). Oxidative damage was highly localized at the hematoma/peri-hematoma border and was decreased by rehabilitation (P=0.004). Lipid content in the peri-hematoma zone was increased by rehabilitation (P=0.016). Rehabilitation reduced the size of calcium deposits (P=0.040) and attenuated persistent dyshomeostasis of Cl - (P<0.001) but not K + (P=0.060). The second study confirmed that rehabilitation decreased hematoma volume (P=0.024). Conclusions - Rehabilitation accelerated clearance of toxic blood components and decreased chronic oxidative stress. As well, rehabilitation attenuated persistent ion dyshomeostasis. These novel effects may underlie rehabilitation-induced neuroprotection and improved recovery of function. Pharmacotherapies targeting these mechanisms may further improve outcome.

Published
2017

43. Tumeurs bénignes du sein : recommandations pour la pratique clinique du Collège national des gynécologues et obstétriciens français (CNGOF) – Texte court [Benign breast tumors: Recommendations of Collège National des Gynécologues Obstétriciens Français (CNGOF) – Short text]

Author

Lavoue, V., Fritel, X., Antoine, M., Beltjens, F., Bendifallah, S., Boisserie-Lacroix, M., Boulanger, L., Canlorbe, G., Catteau-Jonard, S., Chabbert-Buffet, N., Chamming's, F., Chéreau, E., Chopier, J., Coutant, C., Demetz, J., Guilhen, N., Fauvet, R., Kerdraon, O., Laas, E., Legendre, G., Mathelin, C., Nadeau, C., Thomassin Naggara, I., Ngo, C., Ouldamer, L., Rafii, A., Roedlich, M. -N., Seror, J., Séror, J. -Y., Touboul, C., Uzan, C., Darai, E, Oncogenesis Stress Signaling ( OSS ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -CRLCC Eugène Marquis ( CRLCC ), CHU Pontchaillou [Rennes], Service de gynécologie et obstétrique [Poitiers], Université de Poitiers-Centre hospitalier universitaire de Poitiers ( CHU Poitiers ), Centre de recherche en épidémiologie et santé des populations ( CESP ), Université de Versailles Saint-Quentin-en-Yvelines ( UVSQ ) -Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale ( INSERM ), CIC - Poitiers, Université de Poitiers-Centre hospitalier universitaire de Poitiers ( CHU Poitiers ) -Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Theranoscan, Université Pierre et Marie Curie - Paris 6 ( UPMC ), CHU Tenon [APHP], Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc ( CRLCC - CGFL ), Centre Régional de Lutte Contre le Cancer Oscar Lambret, Hôpital Jeanne de Flandres, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] ( CHRU Lille ), Institut Paoli-Calmettes, Fédération nationale des Centres de lutte contre le Cancer (FNCLCC), Pole of Obstetrics and Gynaecology, Senology Unit, Hôpital de Hautepierre [Strasbourg], Centre hospitalier universitaire de Poitiers ( CHU Poitiers ), Hôpital Européen Georges Pompidou [APHP] ( HEGP ), Nutrition, croissance et cancer (U 1069) ( N2C ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université de Tours, UPRES EA 2396, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -UPRES EA 2396, Department of Gynaecology and Obstetrics, Oncogenesis Stress Signaling (OSS), Université de Rennes (UR)-CRLCC Eugène Marquis (CRLCC), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Centre de recherche en épidémiologie et santé des populations (CESP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Université de Poitiers-Centre hospitalier universitaire de Poitiers (CHU Poitiers)-Direction Générale de l'Organisation des Soins (DGOS)-Institut National de la Santé et de la Recherche Médicale (INSERM), Université Pierre et Marie Curie - Paris 6 (UPMC), CHU Tenon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Centre Régional de Lutte contre le cancer Georges-François Leclerc [Dijon] (UNICANCER/CRLCC-CGFL), UNICANCER, Centre Régional de Lutte contre le Cancer Oscar Lambret [Lille] (UNICANCER/Lille), Université de Lille-UNICANCER, Université de Lille, Droit et Santé-Centre Hospitalier Régional Universitaire [Lille] (CHRU Lille), Hôpital Européen Georges Pompidou [APHP] (HEGP), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO), Nutrition, croissance et cancer (U 1069) (N2C), Université de Tours (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM), Développement embryonnaire précoce humain et pluripotence EmbryoPluripotency (UMR 1203), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM)-CHU Montpellier, CHU Saint-Antoine [AP-HP], Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CRLCC Eugène Marquis (CRLCC), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Versailles Saint-Quentin-en-Yvelines (UVSQ), Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Lille Nord de France (COMUE)-UNICANCER, Université de Tours-Institut National de la Santé et de la Recherche Médicale (INSERM), Gynécologie-obstétrique et médecine de la reproduction - Maternité [CHU Tenon], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)-Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Centre Régional de Lutte contre le cancer - Centre Georges-François Leclerc (CRLCC - CGFL), Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Tours, and Université Pierre et Marie Curie - Paris 6 (UPMC)-UPRES EA 2396

Subjects
Mammographie, Benign breast tumour, ésTumeur bénigne du sein, Échographie, Histologie, Sonography, [ SDV ] Life Sciences [q-bio], BI-RADS classification, [SDV]Life Sciences [q-bio], Mammogram, Classification BI-RADS, Pathological analysis, skin and connective tissue diseases
Abstract

National audience; L’échographie est nécessaire avec la mammographie pour explorer une masse clinique du sein (grade B), un écoulement unipore coloré du mamelon (grade C), ou une mastite (grade C). La classification BI-RADS est recommandée pour décrire et classer les anomalies en imagerie du sein. Pour les abcès du sein, une biopsie percutanée est recommandée en cas de masse ou de symptômes persistants (grade C). Pour les mastodynies, lorsque l’imagerie du sein est normale, ni l’IRM, ni une biopsie n’est recommandée (grade C). La biopsie percutanée est recommandée pour les masses classées BI-RADS 4-5 (grade B). Pour les lésions érythémateuses persistantes aréolomamelonnaires ou les lésions d’eczéma atypique, une biopsie est recommandée (grade C). Pour la distorsion ou l’asymétrie mammaire, une macrobiopsie est recommandée en raison du risque de sous-estimation par microbiopsie (grade C). Pour les microcalcifications BI-RADS 4-5 sans signal à l’échographie, une macrobiopsie d’au moins 11 jauges est recommandée (grade B) ; en l’absence de microcalcifications sur les clichés des carottes, des prélèvements supplémentaires sont recommandés (grade B). Pour l’hyperplasie canalaire atypique, l’hyperplasie lobulaire atypique, le carcinome lobulaire in situ, la métaplasie cylindrique avec atypies, la cicatrice radiaire avec traduction radiologique, la mucocèle avec atypie, l’exérèse chirurgicale est habituellement recommandée (grade C). L’abstention est possible après concertation multidisciplinaire (grade C). Pour ces lésions, lorsque l’excision n’est pas in sano, aucune excision complémentaire n’est recommandée sauf pour le CLIS pléomorphe ou avec nécrose (grade C). Pour la phyllode de grade 1, la résection chirurgicale in sano est recommandée ; pour la phyllode de grade 2, des marges de 10 mm sont recommandées (grade C). Pour les lésions papillaires sans atypie, la disparition complète du signal radiologique est recommandée (grade C). Pour les lésions papillaires avec atypies, la résection chirurgicale complète est recommandée (grade C). Summary Breast sonography is required with mammogram to explore clinical breast mass (grade B), colored unipore breast nipple discharge (grade C), or mastitis (grade C). Bi-RADS system is recommended to describe and classify breast-imaging abnormalities. For breast abscess, a percutaneous biopsy is recommended in case of mass or persistent symptoms (grade C). For mastodynia, when breast imaging is normal, no MRI neither breast biopsy is recommended (grade C). Percutaneous biopsy is recommended for BI-RADS 4–5 mass (grade B). For persistent erythematous breast nipple or atypical eczema lesion, a nipple biopsy is recommended (grade C). For distortion and asymmetry, a vacuum core needle biopsy is recommended because of the risk of underestimation by simple core needle biopsy (grade C). For BI-RADS 4–5 microcalcifications without ultrasound signal, a vacuum core needle biopsy of at least 11 gauges is recommended (grade B); in the absence of microcalcifications on radiograph carrots, additional samples are recommended (grade B). For atypical ductal hyperplasia, atypical lobular hyperplasia, lobular carcinoma in situ, flat epithelial with atypia, radial scar, mucocele with atypia, surgical excision is commonly recommended (grade C). Expectant management is feasible after multidisciplinary concertation. For these lesions, when excision is not in sano, no new excision is recommended except for pleomorphic or with necrosis CLIS (grade C). For grade 1 phyllode tumour, in sano surgical resection is recommended; for grade 2 phyllode, 10-mm margins are recommended (grade C). For breast papillary without atypia, complete disappearance of the radiologic signal is recommended (grade C). For breast papillary with atypia, complete surgical excision is recommended (grade C)

Published
2015

44. Moments-based ultrasound visual servoing: from mono to multi-plane approach

Author

Nadeau, C., Krupa, A., Petr, J., Barillot, C., Nadeau, C., Krupa, A., Petr, J., and Barillot, C.

Abstract

This paper presents a new image-based visual servoing approach to control a robotic system equipped with an ultrasound imaging device. The presented method allows an automatic positioning of the probe with respect to an object of interest. Moments-based image features are computed from three orthogonal ultrasound images to servo in-plane and out-of plane motions of the system. An efficient segmentation method, based on graph cut strategy, is proposed to extract the object contour in each image plane. Simulation results demonstrate that this approach improves upon techniques based on a single 2D US image in terms of probe positioning. Our method was also validated from robotic experiments performed on an ultrasound phantom with the use of a motorized 3D probe that provides the three US images.

Published
2016

45. The Canadian Society for Epidemiology and Biostatistics 2016 National Student Conference001INVESTIGATING ECOLOGICAL DETERMINANTS OF MALARIA VECTOR DISTRIBUTION IN RURAL TANZANIA “A MULTI-SCALAR INVESTIGATION”002PREVALENCE AND RISK FACTORS OF TUBERCULOSIS INFECTION AMONG HEALTHCARE TRAINEES IN SOUTH INDIA003SPATIAL MODELLING OF LUNG AND THYROID CANCERS IN UNITED STATES COUNTIES004A MEDIATION ANALYSIS TO ASSESS THE IMPACT OF INHALED CORTICOSTEROIDS (ICSS) DURING PREGNANCY ON BIRTHWEIGHT005MODELLING HUMAN RISK OF WEST NILE VIRUS IN ONTARIO, 2002-2013: INCORPORATING SURVEILLANCE AND ENVIRONMENTAL DATA006EXPLORING THE HEALTH OUTCOMES OF VARIOUS PAN-CANADIAN CERVICAL CANCER SCREENING PROGRAMS USING MICROSIMULATION MODELING007INTEGRATIVE ANALYSIS OF MICRORNA AND GENE EXPRESSION DATA USING SPARSE CANONICAL CORRELATION ANALYSIS008CONDITIONAL DEPENDENCE MODELS UNDER COVARIATE MEASUREMENT ERROR009ASSOCIATION BETWEEN FOOD INSECURITY AND HIV VIRAL SUPPRESSION: A SYSTEMATIC REVIEW AND META-ANALYSIS010ANTIBIOTICS VERSUS APPENDECTOMY FOR UNCOMPLICATED APPENDICITIS: A GLOBAL HEALTH PERSPECTIVE

Author

Homenauth, E, primary, Ghiasi, M, primary, Feldman, L, primary, Arrouf, N, primary, Mallya, S, primary, Lacombe, J, primary, Pichika, SC, primary, Zhao, K, primary, Aibibula, W, primary, Krishnan, R, primary, Kajeguka, D, additional, Kaaya, R, additional, Protopopoff, N, additional, Mosha, F, additional, Desrochers, R, additional, Watts, A, additional, Kulkarni, M, additional, Saravu, K, additional, Nair, S, additional, Mukhopadhyay, C, additional, George, LS, additional, Pai, M, additional, Jiang, H, additional, Brown, P, additional, Blais, L, additional, Lefebvre, G, additional, Samoilenko, M, additional, Jolly, A, additional, Roy-Gagnon, MH, additional, Sander, B, additional, Gauvreau, CL, additional, Memon, S, additional, Popadiuk, C, additional, Flanagan, WM, additional, Nadeau, C, additional, Coldman, AJ, additional, Wolfson, MC, additional, Miller, AB, additional, Acar, E, additional, Cox, J, additional, Hamelin, A-M, additional, McLinden, T, additional, Klein, MB, additional, Brassard, P, additional, Chong, M, additional, and Martin, J, additional

Published
2016
Full Text
View/download PDF

46. A new internet tool to report peritoneal malignancy extent. PeRitOneal MalIgnancy Stage Evaluation (PROMISE) application

Author

Villeneuve, L., primary, Thivolet, A., additional, Bakrin, N., additional, Mohamed, F., additional, Isaac, S., additional, Valette, P.-J., additional, Glehen, O., additional, Rousset, P., additional, Abba, J., additional, Abboud, K., additional, Arvieux, C., additional, Balagué, G., additional, Barrau, V., additional, Rejeb, H.B., additional, Bereder, J.-M., additional, Bibeau, F., additional, Bouzard, D., additional, Brigand, C., additional, Carrère, S., additional, Carretier, M., additional, de Chaisemartin, C., additional, Chassang, M., additional, Chevallier, A., additional, Courvoisier, T., additional, Dartigues, P., additional, Delroeux, D., additional, Desolneux, G., additional, Dohan, A., additional, Dromain, C., additional, Dumont, F., additional, Durand-Fontanier, S., additional, Elias, D., additional, Eveno, C., additional, Evrard, S., additional, Fay, O., additional, Ferron, G., additional, Geffroy, D., additional, Gilly, F.-N., additional, Fontaine, J., additional, Goasguen, N., additional, Ghouti, L., additional, Goéré, D., additional, Guilloit, J.-M., additional, Guyon, F., additional, Heyd, B., additional, Kaci, R., additional, Karoui, M., additional, Kianmanesh, R., additional, Labbé, C., additional, Lacroix, J., additional, Lang-Averous, G., additional, Laverriere, M.-H., additional, Lefevre, J., additional, Lelong, B., additional, Leroux, A., additional, Dico, R.L., additional, Loi, V., additional, Lorimier, G., additional, Marchal, F., additional, Mariani, A., additional, Mariani, P., additional, Mariette, C., additional, Meeus, P., additional, Mery, E., additional, Messager, M., additional, Msika, S., additional, Nadeau, C., additional, Ortega-Deballon, P., additional, Passot, G., additional, Petorin, C., additional, Peyrat, P., additional, Pezet, D., additional, Piessen, G., additional, Pirro, N., additional, Pocard, M., additional, Poizat, F., additional, Porcheron, J., additional, Pourcher, G., additional, Quenet, F., additional, Rat, P., additional, Regimbeau, J.-M., additional, Rousselot, P., additional, Sabbagh, C., additional, Svrcek, M., additional, Tetreau, R., additional, Thibaudeau, E., additional, Tuech, J.-J., additional, Valmary-Degano, S., additional, Vaudoyer, D., additional, Velasco, S., additional, Verriele-Beurrier, V., additional, Wernert, R., additional, and Zinzindohoue, F., additional

Published
2016
Full Text
View/download PDF

47. Using the Cancer Risk Management Model to Evaluate the Health and Economic Impacts of Cytology Compared with Human Papillomavirus DNA Testing for Primary Cervical Cancer Screening in Canada

Author

Popadiuk, C., primary, Gauvreau, C.L., additional, Bhavsar, M., additional, Nadeau, C., additional, Asakawa, K., additional, Flanagan, W.M., additional, Wolfson, M.C., additional, Coldman, A.J., additional, Memon, S., additional, Fitzgerald, N., additional, Lacombe, J., additional, and Miller, A.B., additional

Published
2016
Full Text
View/download PDF

49. Tumeurs bénignes du sein : recommandations pour la pratique clinique du Collège national des gynécologues et obstétriciens français (CNGOF) – Texte court

Author

Lavoué, V., primary, Fritel, X., additional, Antoine, M., additional, Beltjens, F., additional, Bendifallah, S., additional, Boisserie-Lacroix, M., additional, Boulanger, L., additional, Canlorbe, G., additional, Catteau-Jonard, S., additional, Chabbert-Buffet, N., additional, Chamming's, F., additional, Chéreau, E., additional, Chopier, J., additional, Coutant, C., additional, Demetz, J., additional, Guilhen, N., additional, Fauvet, R., additional, Kerdraon, O., additional, Laas, E., additional, Legendre, G., additional, Mathelin, C., additional, Nadeau, C., additional, Thomassin Naggara, I., additional, Ngô, C., additional, Ouldamer, L., additional, Rafii, A., additional, Roedlich, M.-N., additional, Seror, J., additional, Séror, J.-Y., additional, Touboul, C., additional, Uzan, C., additional, and Daraï, E., additional

Published
2015
Full Text
View/download PDF

50. Improving perinatal Group B streptococcus screening with process indicators

Author

Albouy-Llaty, M., Nadeau, C., Descombes, E., Pierre, F., Migeot, V., Eaux, Géochimie organique, Santé (E1), Institut de Chimie des Milieux et Matériaux de Poitiers (IC2MP), Université de Poitiers-Institut national des sciences de l'Univers (INSU - CNRS)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Université de Poitiers-Institut national des sciences de l'Univers (INSU - CNRS)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Visual servoing in robotics, computer vision, and augmented reality (Lagadic), Inria Sophia Antipolis - Méditerranée (CRISAM), Institut National de Recherche en Informatique et en Automatique (Inria)-Institut National de Recherche en Informatique et en Automatique (Inria)-Inria Rennes – Bretagne Atlantique, Institut National de Recherche en Informatique et en Automatique (Inria)-SIGNAUX ET IMAGES NUMÉRIQUES, ROBOTIQUE (IRISA-D5), Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-Télécom Bretagne-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-Université de Rennes (UR)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-Télécom Bretagne-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Institut National des Sciences Appliquées (INSA)-Institut National des Sciences Appliquées (INSA)-Université de Bretagne Sud (UBS)-École normale supérieure - Rennes (ENS Rennes)-Télécom Bretagne-CentraleSupélec-Centre National de la Recherche Scientifique (CNRS), Service de gynécologie et obstétrique [Poitiers], Centre hospitalier universitaire de Poitiers (CHU Poitiers), Université de Poitiers-Institut national des sciences de l'Univers (INSU - CNRS)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS), Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université de Poitiers-Institut de Chimie du CNRS (INC)-Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université de Poitiers-Institut de Chimie du CNRS (INC), CentraleSupélec-Télécom Bretagne-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Institut National de Recherche en Informatique et en Automatique (Inria)-École normale supérieure - Rennes (ENS Rennes)-Université de Bretagne Sud (UBS)-Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-CentraleSupélec-Télécom Bretagne-Université de Rennes 1 (UR1), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-École normale supérieure - Rennes (ENS Rennes)-Université de Bretagne Sud (UBS)-Centre National de la Recherche Scientifique (CNRS)-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA), Institut national des sciences de l'Univers (INSU - CNRS)-Centre National de la Recherche Scientifique (CNRS)-Université de Poitiers-Institut de Chimie du CNRS (INC), Université de Poitiers-Centre National de la Recherche Scientifique (CNRS)-Université de Poitiers-Centre National de la Recherche Scientifique (CNRS), Institut National des Sciences Appliquées - Rennes (INSA Rennes), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Université de Bretagne Sud (UBS)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Rennes (ENS Rennes)-Institut National de Recherche en Informatique et en Automatique (Inria)-Télécom Bretagne-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-CentraleSupélec-Institut National des Sciences Appliquées - Rennes (INSA Rennes), Université de Rennes (UNIV-RENNES)-CentraleSupélec-Institut de Recherche en Informatique et Systèmes Aléatoires (IRISA), Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Institut National des Sciences Appliquées (INSA)-Université de Rennes (UNIV-RENNES)-Université de Bretagne Sud (UBS)-Centre National de la Recherche Scientifique (CNRS)-École normale supérieure - Rennes (ENS Rennes)-Télécom Bretagne-Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-CentraleSupélec, and Université de Poitiers-Centre National de la Recherche Scientifique (CNRS)

Subjects
[CHIM.ORGA]Chemical Sciences/Organic chemistry, [CHIM.CATA]Chemical Sciences/Catalysis, [CHIM.OTHE]Chemical Sciences/Other, ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2012

Catalog

Books, media, physical & digital resources
See catalog results